drugset / Trial / NCT02315001
Liraglutide to Improve corONary Haemodynamics During Exercise streSS
Phase 2
Completed
26 enrolled
King's College London
Guy's and St Thomas' NHS Foundation Trust · collab
RandomizedCrossoverTriple-blind
Summary
A single-centre double-blind placebo-controlled crossover randomised controlled trial to determine the physiological basis of glucagon-like peptide-1 receptor activation on exercise haemodynamics, as manifest through specific electrophysiological parameters measured by serial exercise stress testing, in those patients with reversible myocardial ischaemia and obstructive coronary artery disease confirmed by a baseline exercise test and coronary angiography respectively.
Timeline
- Start
- 2014-01
- Primary completion
- 2015-03
- Completion
- 2015-03
Publications
- Background Myat A, Arri S, Bhatt DL, Gersh BJ, Redwood SR, Marber MS. Design and rationale for the randomised, double-blinded, placebo-controlled Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS) crossover study. Cardiovasc Diabetol. 2015 Feb 19;14:27. doi: 10.1186/s12933-015-0193-4.
- Myat A, Redwood SR, Arri S, Gersh BJ, Bhatt DL, Marber MS. Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS): a double-blind randomised placebo-controlled crossover trial. Diabetol Metab Syndr. 2021 Feb 12;13(1):17. doi: 10.1186/s13098-021-00635-6.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Liraglutide | Peptide | 1.8 mg | Subcutaneous |